Effects of metformin on bone mineral density and bone turnover markers: a systematic review and meta-analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
23 06 2023
Historique:
medline: 26 6 2023
pubmed: 25 6 2023
entrez: 24 6 2023
Statut: epublish

Résumé

Metformin is associated with osteoblastogenesis and osteoclastogenesis. This study aims to investigate the impacts of metformin therapy on bone mineral density (BMD) and bone turnover markers. Systematic review and meta-analysis of randomised controlled trials. Searches were carried out in PubMed, EMBASE, Web of science, Cochrane library, ClinicalTrials.gov from database inception to 26 September 2022. Two review authors assessed trial eligibility in accordance with established inclusion criteria. The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB V.2.0). Data analysis was conducted with Stata Statistical Software V.16.0 and Review Manager Software V.5.3. A total of 15 studies with 3394 participants were identified for the present meta-analysis. Our pooled results indicated that metformin had no statistically significant effects on BMD at lumbar spine (SMD=-0.05, 95% CI= This meta-analysis indicated that metformin had no significant effect on BMD. Metformin decreased some bone turnover markers as N-terminal propeptide of type I procollagen and C-terminal telopeptide of type I collagen. But the outcomes should be interpreted with caution due to several limitations.

Identifiants

pubmed: 37355276
pii: bmjopen-2023-072904
doi: 10.1136/bmjopen-2023-072904
pmc: PMC10314630
doi:

Substances chimiques

Procollagen Type I 0
Metformin 9100L32L2N

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e072904

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Obes Rev. 2019 Oct;20(10):1494-1503
pubmed: 31250977
Bone. 2018 Jul;112:35-41
pubmed: 29654849
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Curr Osteoporos Rep. 2021 Dec;19(6):644-655
pubmed: 34931295
Osteoporos Int. 2017 Jul;28(7):2053-2060
pubmed: 28374044
Clin Chem Lab Med. 2011 Aug;49(8):1271-1274
pubmed: 21605012
Front Cell Dev Biol. 2022 Jan 13;9:777450
pubmed: 35096812
Life Sci. 2023 Jan 1;312:121092
pubmed: 36279968
BMJ. 2015 Jan 02;350:g7857
pubmed: 25555827
J Diabetes Investig. 2021 Feb;12(2):200-206
pubmed: 32623839
J Clin Endocrinol Metab. 2008 May;93(5):1841-5
pubmed: 18319306
J Bone Miner Res. 2020 Dec;35(12):2363-2371
pubmed: 32717111
Clin Exp Rheumatol. 2021 Jul-Aug;39(4):763-768
pubmed: 32828146
Osteoporos Int. 2019 Jun;30(6):1167-1173
pubmed: 30927035
Bone. 2020 Jun;135:115325
pubmed: 32201359
Nat Rev Endocrinol. 2014 Mar;10(3):143-56
pubmed: 24393785
Hepatol Int. 2016 Jan;10(1):169-74
pubmed: 26198758
N Engl J Med. 2007 May 3;356(18):1809-22
pubmed: 17476007
Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):481-5
pubmed: 21726411
Diabetes Res Clin Pract. 2013 Aug;101(2):177-86
pubmed: 23806481
Fertil Steril. 2019 Aug;112(2):362-370
pubmed: 31227287
Lancet Diabetes Endocrinol. 2017 Nov;5(11):908-923
pubmed: 28689768
J Pharm Pharmacol. 2008 Dec;60(12):1695-700
pubmed: 19000376
Mediators Inflamm. 2014;2014:973986
pubmed: 25214721
Trends Endocrinol Metab. 2022 May;33(5):333-344
pubmed: 35307247
J Bone Miner Metab. 2012 Nov;30(6):630-7
pubmed: 22886403
Osteoporos Int. 2016 Jan;27(1):21-31
pubmed: 25990354
PLoS One. 2021 Dec 16;16(12):e0261127
pubmed: 34914744
J Clin Endocrinol Metab. 2010 Jan;95(1):134-42
pubmed: 19875477
J Diabetes Complications. 2010 Sep-Oct;24(5):334-44
pubmed: 19628413
J Clin Endocrinol Metab. 2013 Apr;98(4):1519-28
pubmed: 23450056
J Clin Endocrinol Metab. 2004 Sep;89(9):4331-7
pubmed: 15356029
Maturitas. 2014 Nov;79(3):265-74
pubmed: 25192916
Eur J Endocrinol. 2021 Feb;184(2):299-310
pubmed: 33270043
Calcif Tissue Int. 2022 Dec;111(6):587-596
pubmed: 36190530
Eur J Endocrinol. 2012 Apr;166(4):711-6
pubmed: 22267280
Int J Endocrinol. 2022 Sep 12;2022:6778332
pubmed: 36132487
Chem Biol Drug Des. 2017 Dec;90(6):1056-1066
pubmed: 28456998
JAMA. 1995 Feb 1;273(5):408-12
pubmed: 7823387
J Clin Endocrinol Metab. 2014 Oct;99(10):E1933-42
pubmed: 24905061
Osteoporos Int. 2021 Sep;32(9):1837-1848
pubmed: 33594488
J Bone Miner Res. 2008 Aug;23(8):1334-42
pubmed: 18348689
Exp Clin Endocrinol Diabetes. 2008 Jun;116(6):333-40
pubmed: 18273753
Bone. 2011 Apr 1;48(4):885-93
pubmed: 21147283
Discov Med. 2021 Nov-Dec;32(167):149-154
pubmed: 35221001
J Bone Miner Metab. 2019 Sep;37(5):805-814
pubmed: 30706148
Diabetes Care. 2013 Jun;36(6):1742-8
pubmed: 23704673
Exp Clin Endocrinol Diabetes. 2015 May;123(5):289-95
pubmed: 25607338
Osteoporos Int. 2013 Oct;24(10):2659-70
pubmed: 23644877
J Cell Biochem. 2011 Oct;112(10):2902-9
pubmed: 21618594
Osteoporos Int. 2007 Apr;18(4):427-44
pubmed: 17068657
Diabetes Care. 2008 Feb;31(2):199-203
pubmed: 18024851
Int J Endocrinol. 2022 Feb 28;2022:7808393
pubmed: 35265126
Life Sci. 2019 Jan 1;216:29-38
pubmed: 30414431
Biomed Res Int. 2019 Nov 26;2019:9203934
pubmed: 31886264
Trials. 2020 May 5;21(1):379
pubmed: 32370806
Horm Metab Res. 2015 Jul;47(8):556-9
pubmed: 25671801
Lancet Diabetes Endocrinol. 2020 Apr;8(4):278-291
pubmed: 32109422
J Bone Miner Metab. 2015 Mar;33(2):207-12
pubmed: 24633493
Fertil Steril. 2011 Mar 1;95(3):1059-66.e1-7
pubmed: 21193187
Osteoporos Int. 2010 Dec;21(12):2013-8
pubmed: 20130841
Endocrinol Metab Clin North Am. 2021 Jun;50(2):223-237
pubmed: 34023040
Osteoporos Int. 2021 Nov;32(11):2279-2287
pubmed: 34086101
J Clin Densitom. 2016 Oct;19(4):485-491
pubmed: 27052635
J Bone Miner Metab. 2019 May;37(3):399-410
pubmed: 30032440
J Bone Miner Res. 2010 Feb;25(2):211-21
pubmed: 19594306
Diabetes Res Clin Pract. 2017 Apr;126:202-213
pubmed: 28259010
Cell Commun Signal. 2022 Oct 25;20(1):165
pubmed: 36284303
Osteoporos Int. 2018 Nov;29(11):2517-2526
pubmed: 30027438
Intern Med. 2017;56(11):1301-1306
pubmed: 28566590

Auteurs

Jinhua Hu (J)

Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.

Jingjie Han (J)

Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.

Min Jin (M)

Department of Pharmacy, Shanghai Fourth People's Hospital Affiliated to Tongji University, Shanghai, Shanghai, China.

Jing Jin (J)

Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China zhujialei7582@fckyy.org.cn jinjing6974@fckyy.org.cn.

Jialei Zhu (J)

Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China zhujialei7582@fckyy.org.cn jinjing6974@fckyy.org.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH